Toxicology in Vitro

Official Journal of the European Society of Toxicology in Vitro

Toxicology in Vitro - ISSN 0887-2333
Source Normalized Impact per Paper (SNIP): 0.905 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 0.799 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 2.959 (2019) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 3.049 (2019) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volumes 62-69
Issues: 8 issues
ISSN: 08872333
Editor-in-Chief: Jennings

Personal Subscription

Sales tax will be calculated at check-out Price includes VAT/GST

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Toxicology in Vitro publishes original research papers, reviews and workshop reports focusing on the application and use of in vitro and in silico systems for toxicological evaluations (collectively described as New Approach Methodologies (NAM)). This includes the utilisation or the development of NAMs for assessing the potential adverse effects of chemicals for human safety assessment. In vitro techniques include primary cells, tissue slices, cell lines and stem cells (adult, embryonic and induced Pluripotent cells) or subcellular preparations thereof. Our journal strongly supports the Reduction, Refinement and Replacement (3R) of animals in toxicology evaluations.

This is a wide topic and thus we have certain preferences including:

  • Development of in vitro techniques and their application to research and regulatory use (i.e. 3R principle.
  • Mechanistic underpinning of data.
  • Ability to translate outcome to human safety assessment.
We strongly encourage :
  • The use of normal (non-transformed) human cells (where appropriate).
  • Reporting the Short Tandem Repeat (STR) profile of the cells used (especially when cells have been provided as a gift or generated in house).
  • Free access to raw (or primary) data.
  • Appropriate model characterisation.
  • The use (or reduction) of animal free components, including serum. [Especially when the system was already developed under such conditions, such as the HK-2 cell line].
  • Attention to detailed methodology and appropriate statistics. [Readers need to know how you did the experiment, how many times, how many replicates etc?]
  • Reporting the source of the compounded tested, catalogue no. and lot no. Where the chemical has been purified or synthesised a full analytical report is expected.
  • Quantification of compounds in exposure medium and/or cells over time (biokinetics).


We do not accept solely in vivo investigations and rarely accept animal in vivo, in vitro hybrid papers, except where the animal data was critical in the interpretation or validation of the in vitro data (and not merely confirmatory).


We generally discourage investigations relating:
  • Unidentified mixtures - for example in plant extracts.
  • Solely pharmacological investigations (e.g. demonstrating your chemical kills cancer cells in vitro is not generally acceptable).
  • Use of non-human cells when human equivalents exist and are available.
  • The lack of adherence to established protocols, without direct explanation.
  • Reporting cytotoxicity alone, with no mechanistic underpinning and/or no estimation of chemical exposure.